Navigating approval pathways for immunotherapy in NSCLC: should criteria be revised?

Competing interests

A.D. has been an advisory board member for Amgen, Foundation Medicine and Sanofi. H.J.W. has been an advisory board member for Amgen, AstraZeneca, Boehringer–Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Genentech/Roche, Merck, Mirati, Regeneron, Summit Therapeutics and Takeda. C.J.S. declares no competing interests.

留言 (0)

沒有登入
gif